Team
Management Team
Albert Gianchetti
Chief Executive Officer
Over 30 years of experience in drug development and commercialization, including more than a decade in cardiovascular and metabolic therapeutic areas. Has held senior executive roles across pharma and biotech companies, driving strategy, operations and R&D, with proven ability to raise capital and to lead biotech companies through clinical development. Has directed multiple Phase III and Phase I/II clinical programs and delivered several successful product launches.
Chris Campbell
Senior VP, Technical Operations
Senior Biopharma Executive and CMC strategic leader with 25+ years of experience in biologics, gene therapy, and RNA-based product development.
Proven track record in regulatory approvals, CMC development, and building high-performing CMC organizations. Expertise in process development, technology transfer, regulatory strategy, cross-functional leadership, and strategic partnerships.
Christian Beck, PhD
VP, Corporate & Scientific Development
Scientist by training with 10 years of experience across M&A, corporate finance & strategy, and business development in the biopharma sector, including executing multiple transformational transactions at leading global investment banks such as Lazard and Citi.
Monica Shah, MD, FACC
Chief Medical Officer
Board-certified cardiologist with more than two decades of experience in cardiovascular medicine and drug development across academia, government, and industry. Most recently served as Chief Medical Officer at CTI Clinical Trial & Consulting, and previously held a senior leadership role overseeing cardiovascular gene therapy programs at Rocket Pharmaceuticals. Earlier in her career, spent nearly a decade at the NIH, including as Deputy Chief of Heart Failure and Arrhythmias at the NHLBI.
Jennifer Zimmerman, BSN, RN
VP, Clinical Operations
Clinical operations leader with more than 20 years of experience in pharmaceutical development across biotech, CROs, and academic institutions. Proven success in leading Phase I–III programs focused on rare disease, cardiovascular, CNS, oncology, hematology, infectious disease, and device trials. Passionate about driving clinical excellence and developing key site partnerships.
Cheryl Lee
VP, Operations
Business operator with over 15 years of experience driving growth, optimizing resources and supporting strategic initiatives within complex, high-growth life sciences organizations.
Board of Directors
Andreas Wallnoefer, PhD, MBA
Board Chairman
25 years of experience in biopharma, including 12 years on Roche's R&D Exec Leadership team. Contributed to development of multiple medicines and helped build companies through successful exits.
Albert Gianchetti
Board Member
Nuevocor
Khoo Shih, PhD
Board Member
ClavystBio
Amanda Gett-Chaperot,
PhD, MBA
Board Member
Kurma Partners
Thierry Abribat, PhD
Board Member
Accomplished biotech entrepreneur with a remarkable track record of founding and successfully exiting three biotech companies. Most recently, led Amolyt Pharma from founding to its >$1bn acquisition by AstraZeneca.
Mia Hu, PhD
Board Member
Boehringer Ingelheim Venture Fund
Elia Stupka, PhD
Board Member
Angelini Ventures
Scientific Co-Founders
Brian Burke, PhD
Co-Founder and Advisor
Former Research Director at the Agency for Science, Technology and Research, Singapore. Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex through the innovative use of microscopic and biochemical technologies.
Mark Kay, MD, PhD
Co-Founder and Advisor
Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University.
World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.
Colin Stewart, PhD
Co-Founder and Advisor
Former Research Director at the Agency for Science, Technology and Research, Singapore. Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.
Yann Chong Tan, PhD
Co-Founder and Advisor
Co-founder and former CEO of Nuevocor, who helped established the company as a spin-out of A*STAR and led it through to FDA IND clearance. Brings broad experience spanning venture building and translational research, including as co-founder of Atreca, Inc.